In pancreatic cancer, PRMT1 expression increases after gemcitabine (GEM) treatment, with acquired chemoresistance promoted by delayed clearance of DNA damage markers (e.g., γ H2AX and RPA32), prolonged S‐phase arrest, and improved damage repair mechanisms. This evidence concerns the gene PRMT1 and familial pancreatic carcinoma.